A Practical Predictive Model Based on Ultrasound Imaging and Clinical Indices for Estimation of Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer

References

• DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–451.31577379
   PubMed Web of Science ®Google Scholar
• Vugts G, Maaskant-Braat AJ, Nieuwenhuijzen GA, Roumen RM, Luiten EJ, Voogd AC. Patterns of care in the administration of neo-adjuvant chemotherapy for breast cancer. a population-based study. Breast J. 2016;22(3):316–321. doi:10.1111/tbj.1256826945566
   PubMed Web of Science ®Google Scholar
• Clough KB, Acosta-Marín V, Nos C, et al. Rates of neoadjuvant chemotherapy and oncoplastic surgery for breast cancer surgery: a French National Survey. Ann Surg Oncol. 2015;22(11):3504–3511. doi:10.1245/s10434-015-4378-625665949
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172. doi:10.1016/S0140-6736(13)62422-824529560
   PubMed Web of Science ®Google Scholar
• Abrial SC, Penault-Llorca F, Delva R, et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat. 2005;94(3):255–263. doi:10.1007/s10549-005-9008-816267618
   PubMed Web of Science ®Google Scholar
• Rouzier R, Extra JM, Klijanienko J, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol. 2002;20(5):1304–1310. doi:10.1200/JCO.2002.20.5.130411870173
   PubMed Web of Science ®Google Scholar
• Caudle AS, Yang WT, Mittendorf EA, et al. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. JAMA Surg. 2015;150(2):137–143. doi:10.1001/jamasurg.2014.108625517573
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23(36):9304–9311. doi:10.1200/JCO.2005.02.502316361629
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, Phase 3 trial. Lancet Oncol. 2018;19(1):115–126. doi:10.1016/S1470-2045(17)30716-729175149
   PubMed Web of Science ®Google Scholar
• Kantor O, Sipsy LM, Yao K, James TA, Predictive A. Model for axillary node pathologic complete response after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2018;25(5):1304–1311. doi:10.1245/s10434-018-6345-529368152
   PubMed Web of Science ®Google Scholar
• Davis J Jr, Hoskin TL, Day CN, et al. Performance and clinical utility of models predicting eradication of nodal disease in patients with clinically node-positive breast cancer treated with neoadjuvant chemotherapy by tumor biology. Ann Surg Oncol. 2020;27(12):4678–4686. doi:10.1245/s10434-020-08885-w32729046
   PubMed Web of Science ®Google Scholar
• Zhang J, Xiao L, Pu S, Liu Y, He J, Wang K. Can we reliably identify the pathological outcomes of neoadjuvant chemotherapy in patients with breast cancer? Development and validation of a logistic regression nomogram based on preoperative factors. Ann Surg Oncol. 2021;28(5):2632–2645. doi:10.1245/s10434-020-09214-x33095360
   PubMed Web of Science ®Google Scholar
• Kim WH, Kim HJ, Park HY, et al. Axillary pathologic complete response to neoadjuvant chemotherapy in clinically node-positive breast cancer patients: a predictive model integrating the imaging characteristics of ultrasound restaging with known clinicopathologic characteristics. Ultrasound Med Biol. 2019;45(3):702–709. doi:10.1016/j.ultrasmedbio.2018.10.02630567630
   PubMed Web of Science ®Google Scholar
• Hwang HW, Jung H, Hyeon J, et al. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. Breast Cancer Res Treat. 2019;173(2):255–266. doi:10.1007/s10549-018-4981-x30324273
   PubMed Web of Science ®Google Scholar
• Matsuda N, Hayashi N, Ohde S, et al. A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy. J Surg Oncol. 2014;109(8):764–769. doi:10.1002/jso.2358624647874
   PubMed Web of Science ®Google Scholar
• Park KU, Chen Y, Chitale D, et al. Utilization of the 21-gene recurrence score in a diverse breast cancer patient population: development of a clinicopathologic model to predict high-risk scores and response to neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25(7):1921–1927. doi:10.1245/s10434-018-6440-729679201
   PubMed Web of Science ®Google Scholar
• Tabchy A, Valero V, Vidaurre T, et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 2010;16(21):5351–5361. doi:10.1158/1078-0432.CCR-10-126520829329
   PubMed Web of Science ®Google Scholar
• Vila J, Mittendorf EA, Farante G, et al. Nomograms for predicting axillary response to neoadjuvant chemotherapy in clinically node-positive patients with breast cancer. Ann Surg Oncol. 2016;23(11):3501–3509. doi:10.1245/s10434-016-5277-127216742
   PubMed Web of Science ®Google Scholar
• Zhang F, Huang M, Zhou H, et al. A nomogram to predict the pathologic complete response of neoadjuvant chemotherapy in triple-negative breast cancer based on simple laboratory indicators. Ann Surg Oncol. 2019;26(12):3912–3919. doi:10.1245/s10434-019-07655-731359285
   PubMed Web of Science ®Google Scholar
• Keam B, Im SA, Park S, et al. Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. J Cancer Res Clin Oncol. 2011;137(9):1301–1308. doi:10.1007/s00432-011-0991-321717200
   PubMed Web of Science ®Google Scholar
• Zhu J, Jiao D, Zhao Y, et al. Development of a predictive model utilizing the neutrophil to lymphocyte ratio to predict neoadjuvant chemotherapy efficacy in early breast cancer patients. Sci Rep. 2021;11(1):1350. doi:10.1038/s41598-020-80037-233446717
   PubMed Web of Science ®Google Scholar
• Pu S, Wang K, Liu Y, et al. Nomogram-derived prediction of pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NCT). BMC Cancer. 2020;20(1):1120. doi:10.1186/s12885-020-07621-733213397
   PubMed Web of Science ®Google Scholar
• Kim SY, Cho N, Choi Y, et al. Factors affecting pathologic complete response following neoadjuvant chemotherapy in breast cancer: development and validation of a predictive nomogram. Radiology. 2021;299(2):290–300. doi:10.1148/radiol.202120387133754824
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• Dziak JJ, Coffman DL, Lanza ST, Li R, Jermiin LS. Sensitivity and specificity of information criteria. Brief Bioinform. 2020;21(2):553–565. doi:10.1093/bib/bbz01630895308
   PubMed Web of Science ®Google Scholar
• Corbeau I, Jacot W, Guiu S. Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: a systematic review. Cancers. 2020;12(4). doi:10.3390/cancers12040958
   Web of Science ®Google Scholar
• Okuturlar Y, Gunaldi M, Tiken EE, et al. Utility of peripheral blood parameters in predicting breast cancer risk. Asian Pac J Cancer Prev. 2015;16(6):2409–2412. doi:10.7314/APJCP.2015.16.6.240925824773
   PubMedGoogle Scholar
• Graziano V, Grassadonia A, Iezzi L, et al. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast. 2019;44:33–38. doi:10.1016/j.breast.2018.12.01430611095
   PubMed Web of Science ®Google Scholar
• Asselain B, Barlow W, Bartlett J. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27–39. doi:10.1016/S1470-2045(17)30777-529242041
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–1804. doi:10.1200/JCO.2011.38.859522508812
   PubMed Web of Science ®Google Scholar
• Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer. 2011;47(14):2084–2090. doi:10.1016/j.ejca.2011.06.01421737257
   PubMed Web of Science ®Google Scholar
• Asano Y, Kashiwagi S, Onoda N, et al. Predictive value of neutrophil/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer. Ann Surg Oncol. 2016;23(4):1104–1110. doi:10.1245/s10434-015-4934-026511266
   PubMed Web of Science ®Google Scholar
• Bae SJ, Cha YJ, Yoon C, et al. Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy. Sci Rep. 2020;10(1):13078. doi:10.1038/s41598-020-69965-132753659
   PubMed Web of Science ®Google Scholar
• Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759–771. doi:10.1038/nrc361124154716
   PubMed Web of Science ®Google Scholar
• Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol. 2007;19(2):203–208. doi:10.1016/j.coi.2007.02.00117292599
   PubMed Web of Science ®Google Scholar
• Fu JF, Chen HL, Yang J, Yi CH, Zheng S. Feasibility and accuracy of sentinel lymph node biopsy in clinically node-positive breast cancer after neoadjuvant chemotherapy: a meta-analysis. PLoS One. 2014;9(9):e105316. doi:10.1371/journal.pone.010531625210779
   PubMed Web of Science ®Google Scholar